Diagnosis and Treatment of Non-Neurogenic Overactive Bladder in Adults

Publication Date: September 1, 2019
Last Updated: March 14, 2022

Updated Guideline Statement

Clinicians may consider combination therapy with an anti-muscarinic and β3-adrenoceptor agonist for patients refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists. (Conditional, B)
322859

Overview

Title

Diagnosis and Treatment of Non-Neurogenic Overactive Bladder in Adults

Authoring Organizations